The main goal of the Innovation Cluster is to determine promising areas of research and development, that it is advisable to support the creation of additional infrastructure and financing.

State scientific centre of Virology and Biotechnology “Vector”, Vector-Best, JSC and Medical Biological Union Group have made a great contribution to the development of measures to countering the new coronavirus infection by means of their developments of test systems and vaccines.
Novosibirsk scientists test and diagnose COVID-19 using tests based on PCR (polymerase chain reaction) and loop isothermal amplification (express tests), and also produce kits for determining IgG and IgM antibodies.
Special attention is paid to the development of a vaccine for the prevention and control the epidemic of new coronavirus infection.
Currently, immunogenicity studies of prototype vaccines are being conducted on laboratory animals. During these studies the composition, dose and injection method of the COVID-19 vaccine will be determined. Clinical trials on volunteers will begin in June.
If the vaccine turns out to be effective at this stage, it will be possible to proceed to the next step: “Vector” expects to register the vaccine in September.
The goal of the project is to organize a production facility in accordance with the GMP standard to test production technologies and to produce prototype lots of the agents of innovative biotechnological pharmaceuticals (recombinant proteins, monoclonal antibodies, cytokines, enzymes) for conducting preclinical and clinical trials and for producing stock forms of pharmaceuticals.
The center is planned to manufacture products to be developed on the basis of the research carried out at the Institute of Chemical Biology and Fundamental Medicine, SB RAS (patent holder for more than 20 original compounds), Institute of Cytology and Genetics, SB RAS , and Institute of Clinical Immunology.
The products to be manufactured will include the following items:
- an innovative anti-tumor agent Lactaptin for treatment of breast cancer;
- therapeutic antibodies for the tick-borne encephalitis virus;
- high-performance agents of monoclonal antibodies for treatment of cancer;
- agents of biologically active proteins (interleukines) for treatment of cancer and autoimmune diseases.
In the course of project implementation, we are planning to develop and prepare production of software products for investigative work and information safety communications operators.
Software-hardware complexes and respective design documentation will ensure data-flow computing of actual data, based on application of the methods and algorithms developed during the R&D phase, both in the real-time mode and in the delayed mode, considering the specifics of Big Data. The products developed in the framework of the project will allow formation of patterns of statistical algorithms from the data processed.
As a result of project implementation, the techniques of quantification of pharmaceuticals will be developed, clinically tested and introduced into the medical practice. The method of HPLC, high-performance liquid chromatography, of investigating human blood serum will be used. This will allow medical doctors fully to control the quality of the medical care provided, considering analysis of the mechanisms of pharmaceuticals’ action on the human body and customization of the individual pharmaceutical treatment.
Personalized selection and monitoring of pharmaceutical treatment of socially significant diseases will optimize individual dosage of pharmaceuticals, enhance their effect and prevent by-effects in the treatment of patients.
The existing diagnostic methods of identifying parasitic infections are based on outdated manual methods of microscope investigation of the content of the alimentary tract and of bile samples. These methods depend on qualifications of technicians, the quality of sample preparation, and the time of sample taking and are inadequate for correct diagnostics of these diseases in the acute and chronic phases and provide falsely negative results due to low infection rates.
In the framework of implementation of the complex project under the federal target program "Research and Development in Priority Science and Technology Areas”, a diagnostic kit has been developed and introduced into practice for real-time identification of opisthorchiasis, the most widespread human parasitic infection in the Siberian region. The kit's function is based on real-time identification of the parasite DNA in biological samples with the PCR method. This approach allows automation and simplification of the investigation procedure and significantly raises its reliability.
Currently, based on the existing scientific and engineering experience in the given area, the reagents are being developed to be included into the kit for diagnosing the following parasitic infections: ascariasis, opisthorchiasis, trichiniasis, giardiasis, anisakiasis, diphyllobothriasis, and trichocephaliasis.
To ensure complete acceptance of the already developed and being developed product in the clinical practice, we are planning to hold pilot tests of the product developed in Rospotrebnadzor institutions, to develop and get approvals for methodological recommendations for sanitary and epidemiological laboratories on promotion of new methods and upgrading the existing standards of providing medical care.
It is planned to establish, in the framework of the project, an integrated national database for bioinformatics and science-intensive software development in the area of systems biology and personalized medicine, using unique mathematic methods, computer simulation methods, and IT products and services.
The software being developed will allow essential acceleration of the investigation of molecular and genetic mechanisms of cells, issues and organs’ function by fast processing of retrieval of the required information from super-large volumes of heterogeneous experimental data (Big Data, Semantic Web, Open Linking Data, etc.).
The international-level Center being designed will create a possibility of assessing the risks of disease occurrence and of developing new methods of early molecular diagnostics. Applied software programs of dynamic 3D simulation will enable visualization of the processes taking place in a human body and virtual operations to be performed based on actual data on a patient’s organs (X-ray images, computer tomography, electromagnetic imaging, etc.).